In December 2013 Eli Lilly and Company (NYSE:LLY) acquired all development rights for Arteaus Therapeutics’ calcitonin gene-related peptide (CGRP) antibody upon the completion of a Phase 2a clinical trial for the prevention of frequent, recurrent migraine headaches.
| Headquarters | Cambridge, MA |
| Website | www.arteaus.com​ |
| Pipeline | Multiple Phase 2b trials in progress at Lilly |